Skip to content
OpenCapital
Get started

Organon OGN Change in fair value of contingent consideration

Change in fair value of contingent consideration at other companies

Bausch + Lomb logo
Bausch + LombBLCO
$2M+122%
Biogen logo
BiogenBIIB
——

Other financials

Income statement

See full
Revenue$1.5B-3.5%
Gross profit$783.0M-6.9%
Net income$146.0M+67.8%
EPS (diluted)$0.55+66.7%

Balance sheet

See full
Cash & equivalents$1.1B+104%
Total debt$8.6B-4.3%
Total equity$903.0M+66.6%
Total assets$13.0B-1.2%

Cash flow

See full
Operating cash flow$225.0M+200%
CapEx$37.0M+15.6%
Free cash flow$188.0M+337%

Valuation

See full
Market cap$3.53B-59.4%

Profitability

See full
Gross margin52.8%-4.4pp
Net margin8%-12.3pp
FCF margin11.1%-1.3pp

Returns & leverage

See full
Return on equity71.6%—
Debt / equity9.5×-7.0×
Current ratio2×+0.3×

Where this comes from

Reported directly by Organon in its filing.

Tagged under the XBRL concept us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1.

The official record: Organon’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Organon's change in fair value of contingent consideration.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Organon's change in fair value of contingent consideration?
Organon (OGN) reported change in fair value of contingent consideration of $5M in Q1 2026.
How has Organon's change in fair value of contingent consideration changed year-over-year?
Organon's change in fair value of contingent consideration increased by 145.5% year-over-year, from -$11M to $5M.
What does change in fair value of contingent consideration mean?
Reflects the non-cash adjustments to the fair value of liabilities related to earn-outs or contingent payments from previous business acquisitions. Fluctuations in this value indicate changes in the expected probability of achieving specific performance milestones or regulatory targets. Investors monitor this to assess the accuracy of initial acquisition valuations and the ongoing financial impact of integration outcomes.